ESMO 2025 – little solace for Roche’s doomed TIGIT
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
ESMO 2025 – more ivonescimab shots on goal for Summit
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
ESMO 2025 – domvanalimab flies the flag for TIGIT
Full data from Edge-Gastric are presented at ESMO.
ESMO 2025 – Lilly overshadows Astra’s folate reveal
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
ESMO 2025 – Tubulis keeps the NaPi2b dream alive
The first TUB-040 data come just after Tubulis raised €308m.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
